February 01, 2007
FDA proposed rules revisions
The FDA has proposed rules revisions intended to expand the availability of experimental drugs, to decrease confusion over charging practices for those drugs and improve the safety of them.
The pharma company manufactures the well-known opioid OxyContin.
FDA Commissioner Dr. Scott Gottlieb has been saying all the right things regarding digital health.
Although if approved, it's not likely to launch in the U.S. for quite some time.